Work

Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.3520

Authors: Johanna C. Bendell, Cathy Eng, Kathleen N. Moore, Howard A. Burris, Funda Meric-Bernstam, Suzanne Fields Jones, Sarina Anne Piha-Paul, Jeffrey R. Infante, Vivek Subbiah, Todd Michael Bauer, Lisa Golden, Ji Lin, Ricardo Martinez, Sameera Wijayawardana, Aimee K. Lin, David S. Hong

Institutions: Sarah Cannon, The University of Texas MD Anderson Cancer Center, University of Oklahoma Health Sciences Center, Tennessee Oncology, Eli Lilly (United States)

Language: English

Topic: Colorectal and Anal Carcinomas

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2759018694

Cites:

Cited by: 10

Related to: 10